Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...
Robotic machine learning company Generalist has announced GEN-1, a new physical AI system that it says “crosses into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results